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Background: Male breast cancer (MBC) is rare. Given the paucity of randomized trials, treatment is generally
extrapolated from female breast cancer guidelines.
Methods: This is a retrospective analysis of all male patients presenting with MBC at the Department of Oncology at
University Federico II of Naples between January 1989 and January 2014. We recorded the following data: baseline
characteristics (age, height, weight, body mass index, risk factors, family history), tumor characteristics (side affected,
stage, histotype, hormonal and HER2 status, and Ki-67 expression), treatment (type of surgery, chemotherapy,
endocrine therapy, and/or radiotherapy), BRCA1/2 mutation status (if available), other tumors, and long-term survival.
Results: Forty-seven patients were analyzed. Median age was 62.0 [55.0–72.0]. Among risk factors, obesity and family
history of breast cancer were associated with 21 % and 30 % of MBC cases, respectively. The majority of tumors were
diagnosed at an early stage: stage I (34.0 %) and stage II (44.7 %). Infiltrating ductal carcinoma was the most frequent
histologic subtype (95.8 %). Hormone receptors were generally positive (88.4 % of cases were Estrogen receptor [ER]
positive and 81.4 % Progesteron receptor [PgR] positive). Human epidermal growth factor receptor 2 (HER2) was
positive in 26.8 % of cases; 7.0 % of MBCs were triple negative. The tumor had high proliferation index (Ki67≥ 20 %)
in 64.7 %. Surgery was predominantly mastectomy (85.1 %), whereas quadrantectomy was performed in 14.9 % of
patients. Adjuvant chemotherapy was administered to 70.7 % of patients, endocrine therapy to 90.2 %, trastuzumab
to 16.7 % and radiotherapy to 32.6 %. BRCA status was available for 17 patients: 10 wild-type, 1 BRCA1 carrier, 5 BRCA2
carriers, 1 unknown variant sequence. The overall estimated long-term survival was about 90 % at 5 years, 80 % at
10 years and 70 % at 20 years. Patients carrying a BRCA mutation had a significantly lower survival than patients with
wild-type BRCA (p = 0.04).
Conclusions: Long-term survival was high in MBC patients referred to our clinical unit. Survival was poorer in
BRCA-mutated patients than in patients with wild-type BRCA.
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Male breast cancer (MBC) represents about 1 % of all breast
cancers and approximately 0.2 % of all male cancers [1, 2].
Its incidence is estimated at <1 per 100,000 men-years, and
it appears to be increasing by 1.1 % yearly [1, 2]. However,
given the rarity of this disease, few randomized controlled
trials have been conducted, and most of the data about
MBC come from retrospective studies [3]. Consequently,
treatment of MBC is based on female breast cancer guide-
lines and trials.
Although MBC shares some features of female breast
cancer, it differs significantly in terms of epidemiology
and biologic features. The etiology of MBC is unclear
although anthropometric and hormonal factors appear
to be involved in its development. Clinical disorders,
such as Klinefelter’s syndrome, obesity, liver diseases and
testicular abnormalities, represent risk factors for MBC.
These disorders are associated with an imbalanced estro-
gen/androgen ratio that result in abnormal estrogen ex-
posure [4]. Other risk factors are race and radiation
exposure. Moreover, family history and genetic abnor-
malities, such as mutations of the BRCA1 and BRCA2
genes, play a relevant role in MBC pathogenesis [5].
About 20 % of patients with MBC have a family history
of breast cancer. Subjects with a positive first-degree fam-
ily history have a 2.0-fold increased risk. The risk of MBC
increases to more than 10.0-fold if the number of affected
first-degree relatives are two (i.e. mother and sister), thus
suggesting that genetic factors plays a relevant role in
MBC chance [3, 6]. Accordingly, 2 % of patients with MBC
develop a second primary breast cancer and more than
20 % of patients develop tumors at other sites, most fre-
quently prostate, colon or genitourinary cancer [3]. The
breast cancer susceptibility genes, BRCA1 and BRCA2,
are responsible for a high proportion of cases of heredit-
able breast cancer. Up to 10 % of all MBCs are caused by
inherited germline mutations in either of the two BRCA
genes [7, 8], mutations in BRCA2 being more frequently
recorded in population-based series [8–10]. The esti-
mated lifetime risk of breast cancer is 1–5 % in male
BRCA1-mutation carriers and 5–10 % in male BRCA2-
mutation carriers versus 0.1 % in the general population
[10]. Mutations in these genes are found in MBC patients
with and without a family history of breast and/or ovarian
cancer [11, 12]. Therefore, regardless of family history, all
men with breast cancer should be routinely screened for
BRCA1 and BRCA2 mutations.
Here we report the results of a single-center retrospective
analysis of the clinical features, BRCA status, treatments
and long-term prognosis of patients affected by MBC.
Methods
This is a retrospective analysis of all male patients pre-
senting with MBC at the Department of Oncology atUniversity Federico II of Naples between January 1989
and January 2014. We recorded the following data:
baseline characteristics (age, height, weight, body
mass index, risk factors, family history), tumor char-
acteristics (side affected, stage, histotype, hormonal
and HER2 status, and Ki-67 expression), treatment
(type of surgery, chemotherapy, endocrine therapy,
and/or radiotherapy), BRCA1/2 mutation status (if
available), other tumors, and long-term survival.
Clinico-pathological data were obtained from medical
and pathology reports without performing additional
tests. BRCA1 and BRCA2 mutation analysis was per-
formed in 17 MBC patients within the framework of
a genetic counseling programs ongoing at our center
[13]. BRCA1/2 mutations were classified according to
their potential functional effect as recorded in the
Breast Cancer Information Core (BIC) database [14]
and in the Leiden Open Variation Database (LOVD-
IARC) [15].
Data regarding estrogen receptor (ER), progesterone
receptor (PgR), Ki-67, and HER2 status of breast tu-
mors were extracted from medical, pathology, or
tumor registry records or obtained from the results of
immunohistochemical analysis of sections of formalin-
fixed, paraffin-embedded primary mammary tumor
blocks. HER2 status was assessed by fluorescent in
situ hybridization analysis in ambiguous cases
(immunohistochemistry score = 2+). According to
international guidelines [16], ER and PgR were con-
sidered positive if ≥ 1 % of tumor cell nuclei were im-
munoreactive; whereas Ki-67 was considered high
at ≥ 20 % cut-off.
Follow-up and additional diagnostic exams were
performed according to clinical practice as for fe-
males. Patients were followed with clinical visits,
every 6 months up to 5 years and thereafter annu-
ally. Patients were contacted by phone to update
follow-up and survival status.
All the patients included in this retrospective analysis
provided their informed consent in the framework of
cancer genetic counseling program regulated and ap-
proved by the Local Ethic committee (University
‘Federico II’ of Naples, Prot. 80/00 and 63/02).
Statistical analysis
Continuous variables are expressed as median with
interquartile range (IQR). Categorial variables are
expressed as numbers and percentages. Overall sur-
vival was calculated with the Kaplan Meier method. A
survival analysis for patients who underwent BRCA
testing was performed and statistical significance was
considered for p value <0.05 calculated with the log
rank test. All statistical analyses were performed with
SPSS, version 20.0 (SPSS Inc., Chicago, IL, USA).
Gargiulo et al. BMC Cancer  (2016) 16:375 Page 3 of 11Results
From January 1989 to 1 January 2014, 47 patients re-
ceived diagnosis and treatment for MBC and were
followed at our center (Fig. 1).
Clinical features
The baseline and clinical characteristics of the 47 pa-
tients and BRCA mutational status (if available) are
reported in Table 1. Age at MBC diagnosis ranged be-
tween 33 and 82 years (median: 62.0 years [55.0–72.0]).
Most patients were over the age of 50 years (80.9 %) and
most were diagnosed in the sixth decade of life (Fig. 2).
The median value of the body mass index (BMI) was
26.2 [24.2–28.9] kg/m2. Apart from 10 patients (21.3 %)
classified obese (BMI ≥30 kg/m2), no patient had a his-
tory of clinical disorders associated with an imbalanced
estrogen/androgen ratio such as Klinefelter’s syndrome,
liver diseases or testicular abnormalities. Fourteen of the
47 patients (29.7 %) had a family history of breast or ovar-
ian cancer in first-degree relatives. Nine patients (19.1 %)
had a second tumor unrelated to MBC (one or two
malignancies besides MBC), melanoma and prostate
cancer being the most frequent (3 and 2 cases,
respectively). In addition, gastric cancer, contralateral
breast cancer, thyroid cancer and kidney cancer each
occurred in 1 patient.
Clinico-pathological features
Most tumors were at early TNM stage: stage II
(44.7 %) and 16 were stage I (34.0 %). Only one case
was bilateral (2.1 %).
Pathologic confirmation was available for all 47
patients. Infiltrating ductal carcinoma was the mostFig. 1 Flow chart of the study. Patients with male breast cancer included icommon histologic subtype (45 patients; 95.8 %), whereas
papillary carcinoma was diagnosed in 1 patient and mixed
(tubular-ductal) carcinoma was diagnosed in the remaining
patient. Hormonal status was available for 43 patients: 38
(88.4 %) were ER+ and 35 (81.4 %) were PgR+; the distribu-
tion of both hormone receptors was as follow: 34 cases
were ER+/PgR+ (79.1 %), 4 were ER+/PgR- (9.3 %), 1 was
ER-/PgR+ (2.3 %) and 4 were ER-/PgR- (9.3 %). HER2 sta-
tus was known in 41 patients and was positive in 11 cases
(26.8 %). Triple negative phenotype was revealed in 3 cases
(7 %). In 22 patients (64.7 %) the tumor had high prolifera-
tive activity, namely, Ki67 ≥ 20 %.
Treatments
Data on the surgical approach were available for all pa-
tients. The most frequently used surgical approach was
mastectomy (40 patients, 85.1 %), whereas the remaining
7 patients (14.9 %) underwent quadrantectomy. Positive
axillary nodes were found in 17 of the 44 patients
(38.6 %) who underwent axillary dissection (defined as I/
II lymph nodes level removal). Fourteen of 43 patients
(32.6 %) received post-operative local radiotherapy, while
data were not available for 4/47 patients. The dose used
for adjuvant irradiation was 50 Grey (Gy) in 25–28 frac-
tions (2 Gy/fraction) with an additional boost of 10 Gy if
clinically indicated. The radiotherapy was performed
using the linear accelerator with 6 megavolts photons.
Among patient for whom data are available, systemic
medical treatment consisting of adjuvant chemotherapy
was administered to 29/41 patients (70.7 %): 17 (58.6 %)
received antracycline-based treatment (5 patients re-
ceived both antracycline and taxane); 7 (24.1 %) received
CMF (cyclophosphamide, methotrexate, 5-fluoracil)n the restrospective analysis
Table 1 Baseline and clinical characteristics of the study
population
Characteristics Patients (n = 47)
Age at diagnosis 62.0 [55.0–72.0]
Age at diagnosis
> 50 years 38 (80.9 %)
≤ 50 years 9 (19.1 %)
Body mass index 26.2 [24.2–28.9]
Family history 14 (29.7 %)
Smoker 10 (21.3 %)
Alcohol intake 10 (21.3 %)
Obesity 10 (21.3 %)
Side affected
Left 29 (61.7 %)
Right 17 (36.2 %)
Both 1 (2.1 %)
Tumor stage
I 16 (34.0 %)
II 21 (44.7 %)
III 6 (12.8 %)
IV 1 (2.1 %)
Unknown 3 (6.4 %)
Histotype
Ductal 45 (95.8 %)
Papillary 1 (2.1 %)
Mixed 1 (2.1 %)
Hormone receptor positive
ER 38/43 (88.4 %)
PgR 35/43 (81.4 %)
Both 34/43 (79.1 %)
Unknown 4/47 (8.5 %)
ER+/PgR- 4/43 (9.3 %)
ER-/PgR+ 1/43 (2.3 %)
Hormone receptor negative 4/43 (9.3 %)
HER-2 positive 11/41 (26.8 %)
Unknown 6/47 (12.8 %)
Triple negative 3/43 (7.0 %)
Nodes status
Positive 17/44 (38.6 %)
Negative 27/44 (61.4 %)
Unknown 3/47 (6.4 %)
Ki-67 high-level (cut off 20 %) 22/34 (64.7 %)
Unknown 13/47 (27.7 %)
Surgery
Mastectomy 40 (85.1 %)
Quadrantectomy 7 (14.9 %)
Table 1 Baseline and clinical characteristics of the study
population (Continued)
Radiotherapy 14 /43 (32.6 %) (4 unknown)
Chemotherapy 29/41 (70.7 %) (6 unknown)
Endocrine therapy 37/41 (90.2 %) (6 unknown)
Trastuzumab 7/42 (16.7 %) (5 unknown)
Relapse 9/40 (22.5 %) (6 unknown)
Other tumors 9 (19.1 %)
BRCA test
No 30 (63.8 %)
Yes 17 (36.2 %)
BRCA mutation
BRCA 1 1 (5.9 %)
BRCA 2 5 (29.4 %)
Unknown variant sequence 1 (5.9 %)
Negative 10 (58.8 %)
Death 7 (14.9 %)
No BRCA test 4 (57.1 %)
BRCA 1 1 (14.3 %)
BRCA 2 2 (28.6 %)
Follow-up Median 2660 [1065–4452] days
(7.3 years)
Continuous variables are reported as median and interquartile range
Abbreviations: ER estrogen receptor, PgR progesterone receptor
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taxane. Adjuvant endocrine therapy was administered in
37/41 patients (90.2 %): tamoxifene alone in 29/37 patients
(78.4 %), and 6 patients (16.2 %) were treated with aroma-
tase inhibitors (AIs). The regimen based on tamoxifene
followed by AI was used in 2 cases (5.4 %). Ten of 41
patients (24.4 %) received only endocrine therapy as ad-
juvant; 27 patients (65.9 %) received both chemotherapy
and endocrine therapy in a sequential manner. More-
over, 7 of 42 patients (16.7 %) received trastuzumab
therapy, in 1 case in a metastatic setting.
All patients completed adjuvant treatment program
and no relevant side effects, treatment intolerance or pa-
tients’ refusal were recorded.
Follow-up
Median follow up was 89 months (2660 days, 7.3 years)
(Table 1). During follow-up, 9 patients of 40 (22.5 %),
for whom data about follow-up was available, experi-
enced relapse at the following sites: thoracic wall (n = 4),
bone (n = 4), lung (n = 4), breast (n = 1), brain (n = 1), ax-
illary nodes (n = 1) and adrenal gland (n = 1). The BRCA
test was performed in 17 patients (36.2 %). Ten patients
(58.8 %) were wild-type for BRCA genes, 1 was a carrier
of BRCA1 (5.9 %) and 5 (29.4 %) of BRCA2 mutations,
Fig. 2 Age distribution in patients with MBC. Distribution of the 47 patients with male breast cancer according to age decades
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The characteristics of these 17 patients are reported in
Table 2. The BRCA1 mutation-positive MBC patient
was <40 years old at diagnosis and had a first-degree fam-
ily history of breast and ovarian cancer. No other risk
factors were present. He had an invasive ductal carcin-
oma, stage II, lymph node positive, HER2– and ER
+/PgR+, and low Ki-67 levels. The disease relapsed after
adjuvant treatment (chemotherapy and endocrine ther-
apy) and the patient developed a second tumor (thyroid
cancer). This patient died at 59.8 months of follow-up.
The median age at diagnosis of the 5 BRCA2-positive
patients was 72.0 [62.0–72.5] years, and 2 had a positive
first-degree family history of breast and/or ovarian can-
cer (Table 2). No other risk factors were present. MBC
was an invasive ductal carcinoma in all cases, stage I (3
cases) and III (2 cases); all cases were ER+/PgR+, with
high levels of Ki67, and only 1 was HER2+. Nodal in-
volvement was observed in 2 patients. One patient re-
lapsed after adjuvant treatment (chemotherapy and
endocrine therapy) and 2 developed a second tumor
(one case of prostate cancer, and one of prostate and
kidney cancer) (Table 3).
Seven of 47 patients (15 %) died during follow-up, and
the estimated long-term survival was about 90 % at 5 years,
80 % at 10 years and 70 % at 18–20 years (Fig. 3, Table 3).
Among the patients with a known BRCA status, 3 pa-
tients died and all were mutation carriers. Survival was
significantly lower in BRCA-mutated patients (p = 0.04;
Fig. 4).
Discussion
In this single-center retrospective study, we report the
characteristics of 47 patients with MBC and analyze the
patients’ clinical-pathological features, associated risk
factors, oncological and surgical treatments and long-
term survival. We also evaluated survival in 17 patientswho underwent genetic testing for BRCA1 and BRCA2
mutations.
Median age of our patients at diagnosis was 62 years,
which is similar to previously reported data [17]. Regard-
ing the risk factors associated with MBC, 10/47 of our
patients (21.3 %) had a history of obesity. Obesity is
known to be a risk factor for MBC, and obese men have
an increased risk of about 30 % of breast cancer, similar
to that of postmenopausal women [18]. In men, obesity
is associated with high estrogen levels, and low levels of
testosterone and sex hormone binding globulin, thereby
leading to greater estrogen bioavailability [19, 20].
No patients in our series was affected by Klinefelter’
syndrome, hormonal alterations or chronic liver disease,
which are known risk conditions for MBC [4].
Among genetic risk factors, we found that a family his-
tory of breast or ovarian cancer is as relevant in men as
in women. A positive family history of breast or ovarian
cancer was recorded in 29.7 % of our patients, which is
slightly higher percent than reported previously [3]. Mu-
tational analysis for the BRCA1/2 genes was performed
in 17/47 patients (32.2 %). BRCA2 mutations were found
in five cases (29.4 %) and BRCA1 mutations in only
one patient. Despite the low percentage of patients
who underwent genetic testing, the greater association
with BRCA2 mutations compared to BRCA1 muta-
tions in our MBC patients is in line with a previous
report [5].
Carriers of BRCA1 and BRCA2 mutations genes are at
an increased risk for cancer at body sites other than
breast, such as prostate, stomach, pancreatic cancers and
melanoma [3]. According to previous data, about 19 %
of our patients developed a second tumor [3].
The role of family history, germinal mutation of
BRCA1/2 genes, risk of cancers associated to breast and
ovarian cancer syndrome related to BRCA1/2 genes,
suggest that cancer genetic counseling for MBC patients
Table 2 Characteristics of patients with known BRCA status
Characteristics BRCA-negative BRCA1-positive BRCA2-positive BRCA UVS
n = 10 n = 1 Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 n = 1
Age at diagnosis 61.0 [53.8–67.3] 30–40 60–70 70–80 70–80 60–70 70–80 70–80
BMI 26.2 [23.6–32.0] 22.8 24.5 33.6 27.0 23.2 31.4 25.8
Family history 50 % Yes No Yes No No Yes No
Smoke 0 % No Yes No Yes No No No
Alcohol intake 10 % No Yes No No No Yes No
Obesity 20 % No No Yes No No Yes No
Side Left (70 %); Right (30 %) Right Right Right Left Both Left Left
Stage I (20 %); II (70 %); III (10 %) II I III III Unknown I I
Histotype Ductal (100 %) Ductal Ductal Ductal Ductal Ductal Ductal Ductal
HR status ER+/PgR+ 9 ER+/PgR ER+/PgR ER+/PgR ER+/PgR ER+/PgR ER+/PgR ER+/PgR
Unknown 1 + + + + + + +
Node status, positive 50 % Yes No Yes Yes No No No
HER-2 positive 10 %
Unknown (10 %)
No No No Yes No No No
Ki-67 high-level (cutoff 20 %) 60 %
Unknown (10 %)
No Unknown Yes Yes Yes Yes Yes
Surgery M 90 % M M M Q M M M
Radiotherapy 50 % No No No Yes No No No
Chemotherapy 60 %
Unknown (10 %)
Yes Yes Yes Unknown Yes No Yes
Endocrine therapy 90 %
Unknown (10 %)
Yes Yes Yes Unknown Yes Unknown Yes
Trastuzumab 10 %
Unknown (10 %)
No No No Unknown No No No
Relapse 20 % Yes No Yes Yes Unknown No No
Other tumors 20 % Yes No No Yes Yes No No
Follow-up (days) 3152 [701–6735] 1795 3845 2892 1096 7069 1031 918
For single patients, age is reported as decade range to maintain participant confidentiality
Abbreviations: BMI body mass index, ER estrogen receptor, HR hormone receptor, M mastectomy, PgR progesterone receptor, Q quadrantectomy, UVS unknown
variant sequence
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correlations and to personalize surveillance strategies ac-
cording to international guidelines (http://www.nccn.org/
professionals/physician_gls/f_guidelines_nojava.asp#site).
We found that T stage at diagnosis was heterogeneous,
but 44.7 % of our patients were at stage II with axillary
lymph node involvement in almost half of these cases
(40.5 %). Despite the small sample size, stage at diagno-
sis was in line with previously described in a larger
report [21]. Because of the lower level of awareness
among men, and a low index of suspicion for the disease
there is often a diagnostic delay. Moreover, a screening
program is not available for men because of the low
lifetime risk [9].
In the present study, there was a left-sided preponder-
ance over the right side (61.7 % versus 36.2 % respectively)
consistent with a previous report [21]. As expected, themost prevalent histological subtype was invasive ductal
carcinoma. Our data confirm the high rate of hormone-
receptor positivity associated with MBC [22]. In fact, 88.4 %
of our MBC patients were ER+ and 81.4 % PgR+. We
found that 26.8 % of our patients were HER2 positive.
Data on HER2 status in MBC is very heterogeneous,
with HER2 overexpression rates ranging from 2 % to
42 % [23–26].
The most frequently used surgical procedure for loco-
regional treatment of MBC is modified radical mastec-
tomy (MRM) and it was performed in 40 of our patients
(80.5 %), which is consistent with a previous study [27].
This approach is probably preferred given the anatomic
characteristics of male breast tissue, the limited surgical
sequelae and the better cosmetic outcome compared to
other procedures [3, 28]. Most of our patients under-
went axillary dissection, as suggested in the literature
Table 3 Characteristics of patients who died
Characteristics Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7
Age at diagnosis 40–50 50–60 30–40 70–80 70–80 70–80 50–60
Body mass index 20.7 27.0 22.8 27.0 31.4 29.0 25.0
Family history No No Yes No Yes No No
Smoke No No No Yes No No No
Alcohol intake No Yes No No Yes No No
Obesity No No No No Yes No No
Side Left Left Right Left Left Right Left
Stage IV II II III I III Unknown
Histotype Ductal Ductal Ductal Ductal Ductal Ductal Ductal
HR status ER+ ER-/PgR- ER+/PgR+ ER+/PgR+ ER+/PgR+ ER+/PgR+ Unknown
HER-2 positive Yes Unknown No Yes No No Unknown
Ki-67 high-level (cutoff 20 %) Unknown Unknown No Yes Yes Yes Unknown
Surgery M M M Q M M M
Radiotherapy Yes No No Yes No No No
Chemotherapy Yes Yes Yes Unknown No Yes No
Endocrine therapy Yes No Yes Unknown Unknown Yes No
Trastuzumab Yes No No Unknown No No No
Relapse Yes No Yes Yes No Unknown Yes
Other tumors Yes No Yes Yes No No Yes
BRCA mutation No test No test BRCA 1 BRCA 2 BRCA 2 No test No test
Follow-up (days) 2465 5706 1795 1096 1031 173 3713
For single patients, age is reported as decade range to maintain participant confidentiality
Abbreviations: ER estrogen receptor, HR hormone receptor, M mastectomy, PgR progesterone receptor, Q quadrantectomy
Fig. 3 Survival in patients with MBC. Kaplan-Meier survival estimates in the 47 patients with MBC included in the study
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Fig. 4 Survival in patients with known BRCA mutation status. Kaplan-Meier survival estimates in the 17 patients underwent to BRCA test and stratified
for mutational status
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node (SLN) is a reliable tool in MBC patients, as shown
in recent experiences [29–31].
The criteria for administration of post-surgical radi-
ation are usually extrapolated from data obtained in
women, due to the absence of controlled trials [32]. In
the present series, postoperative radiotherapy was per-
formed in 14 of 43 patients (32.6 %) and 7 of them re-
ceived post-mastectomy radiotherapy. Several studies
showed that radiation reduces the post-operative loco-
regional recurrence rate [33–36], but only one study
demonstrated a survival benefit [36].
In our study, tamoxifen was the most frequent adju-
vant hormone therapy and AIs alone were used in 6
(16.2 %) patients. Endocrine therapy was found to be
beneficial in small retrospective studies [37–39]. In the
study by Goss et al. [39] adjuvant hormone treatment
with tamoxifen significantly improved disease-free and
overall survival, thereby representing the standard of
care. The role of AIs in male patients is not as clear as it
is for women. Monotherapy with AIs does not com-
pletely restrain estrogen production because they do not
inhibit the testicular production of estrogen, which
represents 20 % of circulating estrogen [40]. Moreover,
AI administration causes an increase in the levels of
luteinizing hormone and follicle stimulating hormone
that could lead to an increase in the substrate for
aromatization, suggesting that AIs could be used in com-
bination with a luteinizing hormone-releasing hormone
analog [41]. Aromatase inhibitors are mainly used in
metastatic patients who are resistant to tamoxifen or
with contraindications to tamoxifen therapy [41].The role of chemotherapy in MBC is not well defined
and only CMF has been prospectively evaluated in the
adjuvant setting [42, 43]. In the study conducted by
Giordano et al., 63 % of patients undergoing systemic
treatment received chemotherapy (alone or in combin-
ation with hormone therapy) and anthracycline-based
chemotherapy, more frequently used than CMF (81 %
versus 16 %), had a reduced risk of death [44]. In our
series, adjuvant chemotherapy was administered to 29
patients (70.7 %) and antracycline-based treatment (with
or without taxane) was the preferred regimen. The pa-
tient’s evaluation was performed considering different
clinical and pathological features such as tumor stage,
ER/PgR and Ki-67 level, HER-2 status, age and comor-
bidities, as commonly done in female BC patients, in
order to select those who may benefit from systemic
treatment. The high percentage of patients undergoing
chemotherapy could be explained by the following
considerations: 1) 40 % of patients had nodal positive
disease; 2) patients with hormone-receptors negative dis-
ease were considered at high-risk and received chemother-
apy, particularly, those patients with triple negative
phenotype (7 % of patients); 3) patients with HER-2 positive
disease were treated with trastuzumab plus chemotherapy
(roughly 27 % of patients); 4) 65 % of patients were found
to have high levels of Ki-67; 5) no patients refused treat-
ment or presented age-related comorbidities contraindi-
cating chemotherapy; 6) the majority of the patients
included in our series received diagnosis of MBC after
2000s (Fig. 1).
In our series, the estimated long-term survival was
about 90 % at 5 years, 80 % at 10 years and 70 % at 18–20
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patients compared to data reported in literature. MBC has
a worse overall prognosis than female breast cancer,
namely, an overall 5-year survival rate of 40–65 % versus
85 % in women [45]. However, when matched for stage,
age and prognostic factors, the prognosis is similar [45].
The worse outcome in men seems primarily due to the
presence of more advanced disease at diagnosis, and
gender itself does not seem to be a prognostic factor
[46]. Evidence on survival in MBC is quite small com-
pared with female BC and the wide range of survival de-
scribed likely reflects the heterogeneity of disease stage
and different treatments strategies across time. Our high
rates of survival might be related to several aspects such
as patient characteristics, tumor features, and treatments
strategies adopted. To better put our results into the con-
text of previous literature, the following considerations
should be taken into account: 1) the most important prog-
nostic factors in MBC seem to be patient age, tumor stage
and lymph node status. Fentiman et al. reported 5-year
survival rates of 75–100 % for stage I, 50–80 % for
stage II, and 30–60 % for stage III [47]. Additionally,
some data showed that 40 % of patients with MBC will
die for other causes [3], likely reflecting the influence of
comorbidities and older mean age at diagnosis. Most of
our patients were diagnosed in the sixth decade of life
and at early TNM stage (approximately 79 % stage I-II),
without significant age-related comorbidities contraindi-
cating the treatment; 2) 90 % of our patients received
hormone therapy, mainly tamoxifen which demonstrated
to decrease recurrence and improve overall survival [39];
3) 70 % of our patients received adjuvant chemotherapy
and previous studies showed that patients undergoing
chemotherapy have survival benefits compared to those
without chemotherapy [45, 46]. Moreover, most of our
patients received antracycline and/or taxanes rather than
CMF, and this was previously found to be associated
with better survival in female disease; 4) trastuzumab
was used in all HER2 positive disease and it is well-
known to improve survival in female BC.
Obviously, we cannot draw definitive conclusions on
the impact of each factor on the overall survival, how-
ever, this experience could be useful for the current
limited knowledge on MBC and for driving future pro-
spective studies.
In women, BRCA-associated BC tends to manifest
specific genotype–phenotype correlations [48], whereas
little is known about the phenotype characteristics of
BRCA-associated MBC. A recent study identified more
high-grade, progesterone-receptor negative, HER2-positive
disease in male patients who carried BRCA2 mutations [9],
and earlier research found poorer prognosis in men with
BRCA2-associated tumors [9]. Interestingly, we found that
patients with BRCA mutation showed a low survivalcompared with BRCA wild-type. Despite small size, this
is the second study on association with prognosis and
BRCA status. Our data are consistent with the poorer
prognosis previously reported [9].
One of the limits of this study is its retrospective na-
ture and the small number of patients enrolled. How-
ever, it is difficult to conduct randomized trials or large
multicenter studies because of the rarity of MBC. Other
limitations are: 1) the presence of some missing data;
and 2) the availability of BRCA status just for 17 pa-
tients. However, many of our patients have a long-term
follow-up and some were referred to our center in the
1990s when BRCA testing was not a routine procedure.
Conclusion
This study has shown a high long-term survival rate in
patients with MBC compared with other studies. A sig-
nificantly reduced survival rate was registered in the
subgroup of patients carrying BRCA1/2 mutations in
line with the poorer prognosis previously reported in the
same setting. MBC remains a challenge and future larger
studies are warranted. However, given the low incidence
of the disease, prospective studies are difficult to plan,
and retrospective data collections such as our series play
an important role in acquiring information about MBC.
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